7. Vaglio S, Arista MC, Perrone MP, Tomei G, Testi AM, Coluzzi S, et al. Autoimmune hemolytic anemia in childhood: serologic features in 100 cases. Transfusion 2007;47:50–4.
8. Sankaran J, Rodriguez V, Jacob EK, Kreuter JD, Go RS. Autoimmune hemolytic anemia in children: Mayo clinic experience. J Pediatr Hematol Oncol 2016;38:e120–4.
10. Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol 2002;69:258–71.
11. Michel M. Classification and therapeutic approaches in autoimmune hemolytic anemia: an update. Expert Rev Hematol 2011;4:607–18.
12. Petz LD, Garratty G. Immune hemolytic anemias. 2nd ed. Philadelphia (PA): Churchill Livingstone, 2004.
17. Berentsen S, Tjønnfjord GE. Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. Blood Rev 2012;26:107–15.
20. Birgens H, Frederiksen H, Hasselbalch HC, Rasmussen IH, Nielsen OJ, Kjeldsen L, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol 2013;163:393–9.
22. Roumier M, Loustau V, Guillaud C, Languille L, Mahevas M, Khellaf M, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients. Am J Hematol 2014;89:E150–5.
23. Naithani R, Agrawal N, Mahapatra M, Kumar R, Pati HP, Choudhry VP. Autoimmune hemolytic anemia in children. Pediatr Hematol Oncol 2007;24:309–15.
25. Packman CH. Hemolytic anemia due to warm autoantibodies. Blood Rev 2008;22:17–31.
26. Meyer O, Stahl D, Beckhove P, Huhn D, Salama A. Pulsed high-dose dexamethasone in chronic autoimmune haemolytic anaemia of warm type. Br J Haematol 1997;98:860–2.
27. Ozsoylu F. Megadose methylprednisolone for the treatment of patients with Evans syndrome. Pediatr Hematol Oncol 2004;21:739–40.
28. Dussadee K, Taka O, Thedsawad A, Wanachiwanawin W. Incidence and risk factors of relapses in idiopathic autoimmune hemolytic anemia. J Med Assoc Thai 2010;93 Suppl 1:S165–70.
29. World Health Organization. Guideline on haemoglobin cutoffs to define anaemia in individuals and populations. Geneva (Switzerland): World Health Organization, 2024.
30. Arceci R, Hann IM, Smith OP. Pediatric hematology. Oxford: Blackwell Publishing, 2006.
31. Delvin EE, Marcil V, Lambert M, O'Loughlin J, Paradis G, Levy E. Pediatric reference intervals for biochemical markers in a Caucasian population. Clin Chem Lab Med 2011;49:1093–102.
32. Soldin SJ, Wong EC. Pediatric reference intervals. Washington, DC: AACC Press, 2017.
33. Li BJ, Yuan X, Jiang YJ, Li N, Shu XW, Liu KL. Retrospective analysis of 30 severe autoimmune hemolytic anemia patients treated by whole blood exchange transfusion. Transfusion 2015;55:2231–7.
37. Michel M, Saïr M, Rivière E, Moulis G, Comont T, Costedoat-Chalumeau N, et al. Intravenous immunoglobulin as a rescue therapy for severe adult autoimmune hemolytic anemia: results from a French multicenter observational study. Am J Hematol 2024;99:1616–9.
38. Flores G, Cunningham-Rundles C, Newland AC, Bussel JB. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol 1993;44:237–42.
39. Barcellini W, Zaninoni A, Giannotta JA, Fattizzo B. New insights in autoimmune hemolytic anemia: from pathogenesis to therapy stage 1. J Clin Med 2020;9:3859.
40. Fan J, He H, Zhao W, Wang Y, Lu J, Li J, et al. Clinical features and treatment outcomes of childhood autoimmune hemolytic anemia: a retrospective analysis of 68 cases. J Pediatr Hematol Oncol 2016;38:e50–5.